中国医学创新2019，Vol.16Issue(1)：9-13,5.DOI:10.3969/j.issn.1674-4985.2019.01.003
右美托咪定在胸交感链切除术ERAS管理中脑保护效应
Protective Effect of Dexmedetomidine on ERAS during Thoracoscopic Sympathectomy
摘要
Abstract
Objective:To explore the protective effect of Dexmedetomidine on ERAS management in thoracoscopic sympathectomy.Method:70 cases of thoracoscopic sympathectomy in our hospital from February2016 to September 2018 were selected, they were randomly divided into control group and Dexmedetomidine group, 35 cases in each group.The Dexmedetomidine group was given 1μg/kg, intravenous injection for 10minutes, then pumped into the operation with 0.4μg/ (kg·h), the control group was given the same amount of saline.The MAP, HR, SpO2 and rSO2 of two groups at different time points were compared.The Serum S100beta levels of two groups were measured.The Ramsay sedation score, length of stay and hospitalization cost of two groups were observed after extubation.Result:Compared with T0, the rSO2 levels of two groups at T4decreased significantly (P<0.05), HR increased significantly in the control group at T2 and T6 than those of Dexmedetomidine group (P<0.05).After treatment, the S100βin the Dexmedetomidine group was lower than that of control group (P<0.05), the Ramsay score in the Dexmedetomidine group was higher than that of the control group (P<0.05), the hospitalization time and hospitalization expenses in the Dexmedetomidine group were shorter than those of the control group (P<0.05).Conclusion:Dexmedetomidine can maintain hemodynamic stability, it has lower S100βlevel, better sedation level after extubation, shorter hospitalization time and lower hospitalization expenses.关键词
右美托咪定/胸交感链切除/ERAS/脑保护Key words
Dexmedetomidine/Thoracoscopic sympathectomy/ERAS/Cerebral protection引用本文复制引用
邱荣宗,郑思屏,刘航辉..右美托咪定在胸交感链切除术ERAS管理中脑保护效应[J].中国医学创新,2019,16(1):9-13,5.基金项目
惠州市科技计划项目(2017Y046) （2017Y046）
